Earlier this year, Genetix reported that tumors themselves can be genetically engineered to secrete these and other anti-angiogenic
proteins and thereby cause their own demise.
Also, since bevacizumab is an anti-angiogenic
and inhibits blood flow to tumors, this trial will analyze the vascular effects of bevacizumab with chemotherapy.
After a preliminary scientific evaluation of AE-941, comparing its biological activities and safety profile to other anti-angiogenic
products, the partner has agreed to enter into this co-development project.
Thus combining these two agents with distinct but complementary anti-angiogenic
mechanisms provides synergistic anti-tumor effects and completely eradicates tumors resulting in dramatic cures and improvement in survival.
These findings demonstrate the potential utility of intramuscular delivery of a formulated plasmid for the treatment of disseminated cancers using any anti-angiogenic
factor and not only endostatin.
Table 55: Anti-angiogenic
Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
Information on most companies active in anti-angiogenic
R&D in oncology
In the current study, however, researchers treated the mice only with rRp450 and the anti-angiogenic
Tumor specificity of anti-angiogenic
agents (Rixe, Kelly, Giaccone)
The CD-ROM searchable database reflects the most recent advances in the field of anti-angiogenic
drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes.
P529 is a non-steroidal, synthetic, small molecule dual acting anti-angiogenic
and direct anti-tumor agent created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work.
today announced new data highlighting the anti-angiogenic
and tumor-targeting properties of TM601 in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
April 11 /PRNewswire/ -- Researchers at Southern Research Institute today announced that they have developed a novel mouse model and in vitro and in vivo assays to help preclinical drug researchers in the discovery of anti-angiogenic
agents for cancer treatment.
today announced that new data highlighting the anti-angiogenic
and tumor-targeting properties of TM601 will be discussed in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held May 29-June 2, 2009 in Orlando, FL.
Food and Drug Administration to study its anti-angiogenic
drug, A6, in patients with advanced gynecologic cancers.